UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Platform Trials — Beware the Noncomparable Control Group

The New England journal of medicine, 2021-04, Vol.384 (16), p.1572-1573

2021

Volltextzugriff (PDF)

Outcome-Adaptive Randomization: Is It Useful?

Journal of clinical oncology, 2011-02, Vol.29 (6), p.771-776

2011

Volltextzugriff (PDF)

Time trends with response-adaptive randomization: The inevitability of inefficiency

Clinical trials (London, England), 2022-04, Vol.19 (2), p.158-161

2022

Volltextzugriff (PDF)

Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?

Clinical cancer research, 2018-05, Vol.24 (10), p.2239-2240

2018

Volltextzugriff (PDF)

The Cross-Validated Adaptive Signature Design

Clinical cancer research, 2010-01, Vol.16 (2), p.691-698

2010

Volltextzugriff (PDF)

Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

Clinical cancer research, 2005-11, Vol.11 (21), p.7872-7878

2005

Volltextzugriff (PDF)

Are restricted mean survival time methods especially useful for noninferiority trials?

Clinical trials (London, England), 2021-04, Vol.18 (2), p.188-196

2021

Volltextzugriff (PDF)

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2439-2442

2011

Volltextzugriff (PDF)

Reply to Quartagno et al

Clinical trials (London, England), 2021-12, Vol.18 (6), p.746-746

2021

Volltextzugriff (PDF)

Randomized Phase II Trial Designs With Biomarkers

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3304-3309

2012

Volltextzugriff (PDF)

Noninferiority trials with nonadherence to the assigned randomized treatment

Clinical trials (London, England), 2019-12, Vol.16 (6), p.673-681

2019

Volltextzugriff (PDF)

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7199-7206

2005

Volltextzugriff (PDF)

Targeting epidermal growth factor receptor—are we missing the mark?

The Lancet (British edition), 2003-07, Vol.362 (9377), p.62-64

2003

Volltextzugriff (PDF)

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

Clinical cancer research, 2008-07, Vol.14 (14), p.4368-4371

2008

Volltextzugriff (PDF)

Design Issues in Randomized Phase II/III Trials

Journal of clinical oncology, 2012-02, Vol.30 (6), p.667-671

2012

Volltextzugriff (PDF)

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3791-3796

2008

Volltextzugriff (PDF)

Evaluation of Randomized Discontinuation Design

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5094-5098

2005

Volltextzugriff (PDF)

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Blood cancer journal (New York), 2022-06, Vol.12 (6), p.98-98, Article 98

2022

Volltextzugriff (PDF)

Adaptive randomization versus interim monitoring

Journal of clinical oncology, 2013-03, Vol.31 (7), p.969-970

2013

Volltextzugriff (PDF)

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007

Journal of clinical oncology, 2010-12, Vol.28 (35), p.5197-5201

2010

Volltextzugriff (PDF)

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2007-03, Vol.25 (7), p.760-766

2007

Volltextzugriff (PDF)

Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials

The cancer journal (Sudbury, Mass.), 2019-07, Vol.25 (4), p.254-263

2019

Volltextzugriff (PDF)

Marker Sequential Test (MaST) design

Clinical trials (London, England), 2014-02, Vol.11 (1), p.19-27

2014

Volltextzugriff (PDF)

NCI―RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers

JNCI : Journal of the National Cancer Institute, 2013-01, Vol.105 (1), p.11-24

2013

Volltextzugriff (PDF)

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1712-1721

2009

Volltextzugriff (PDF)

1 – 25 von 173

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(156)
Mit Volltextzugriff
(158)

Publikationsform

Sprache

Englisch
(173)

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Life Sciences & Biomedicine
(122)
Humans
(110)
Oncology
(72)
Research Design
(51)
Clinical Trials
(40)
Medical Sciences
(34)
Biological And Medical Sciences
(32)
Medicine, Research & Experimental
(28)
Research & Experimental Medicine
(28)
Mathematics
(27)
Randomized Controlled Trials As Topic
(26)
Physical Sciences
(25)
Statistics & Probability
(25)
Treatment Outcome
(24)
Tumors
(22)
Data Interpretation, Statistical
(21)
Mathematical & Computational Biology
(21)
Neoplasms - Drug Therapy
(21)
Sample Size
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Platform Trials — Beware the Noncomparable Control Group

Outcome-Adaptive Randomization: Is It Useful?

Time trends with response-adaptive randomization: The inevitability of inefficiency

Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?

The Cross-Validated Adaptive Signature Design

Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients

Are restricted mean survival time methods especially useful for noninferiority trials?

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

Reply to Quartagno et al

Randomized Phase II Trial Designs With Biomarkers

Noninferiority trials with nonadherence to the assigned randomized treatment

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Targeting epidermal growth factor receptor—are we missing the mark?

Multi-Arm Clinical Trials of New Agents: Some Design Considerations

Design Issues in Randomized Phase II/III Trials

Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

Evaluation of Randomized Discontinuation Design

Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee

Adaptive randomization versus interim monitoring

Accrual Experience of National Cancer Institute Cooperative Group Phase III Trials Activated From 2000 to 2007

Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer

Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials

Marker Sequential Test (MaST) design

NCI―RTOG Translational Program Strategic Guidelines for the Early-Stage Development of Radiosensitizers

Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005

Suchergebnisse filtern